<DOC>
	<DOCNO>NCT01579578</DOCNO>
	<brief_summary>The purpose study assess efficacy safety PK AZD8931 plus paclitaxel versus paclitaxel alone patient metastatic , gastric gastro-oesophageal junction , cancer .</brief_summary>
	<brief_title>Assess Efficacy AZD8931 Combination With Paclitaxel Versus Paclitaxel Alone Patients With Gastric Cancer</brief_title>
	<detailed_description>A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study Assess Efficacy , Safety Pharmacokinetics AZD8931 Combination Paclitaxel versus Paclitaxel alone Patients Metastatic , Gastric Gastro-oesophageal Junction , Cancer progress follow First Line Therapy Ineligible Treatment trastuzumab HER2 Status ( SAGE )</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Male female age 18 year old ( 20 year old Japan ) Patients must radiologically confirm progression follow 1st line fluoropyrimidine platinum base treatment metastatic gastric cancer ( date progression start first line treatment capture database ) Suitable paclitaxel therapy . At least one lesion , previously irradiate chosen mandatory fresh tumour biopsy study screen period , accurately measure baseline compute tomography ( CT ) magnetic resonance imaging ( MRI ) suitable accurate repeat assessment . Ineligible trastuzumab treatment local assessment . This include IHC analysis determine HER2 status test FISH/CISH consider part local practice . Eligible patient define ; HER2 IHC 0 , HER2 IHC +1 +2 Have receive 1 prior chemotherapy regimen metastatic gastric cancer . ( chemotherapy adjuvant treatment permit ) . Any prior taxane therapy ( time diagnosis gastric cancer ) Any prior therapy inhibitor ErbB1 ( EGFR ) ErbB2 ( HER2 ) ( eg , lapatinib ) Resting ECG measurable QTc ( F ) interval great 480 msec 2 time point within 24 hour period ( see section 6.4.9.1 ) Unresolved toxicity grater CTCAE grade 2 ( except alopecia ) previous anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Metastatic Gastric Cancer progress follow First Line Therapy Ineligible Treatment trastuzumab HER2 Status</keyword>
</DOC>